These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36837551)

  • 21. Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
    Bang YH; Hong YS; Lee JS; Lee KW; Han HS; Kim SY; Kim JW; Kim HK; Kim JW; Eun CK; Kim TW; Kim JE
    Clin Colorectal Cancer; 2021 Jun; 20(2):101-112.e6. PubMed ID: 33223477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
    Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
    Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study.
    Lee B; Wong HL; Tacey M; Tie J; Wong R; Lee M; Nott L; Shapiro J; Jennens R; Turner N; Tran B; Ananda S; Yip D; Richardson G; Parente P; Lim L; Stefanou G; Burge M; Iddawela M; Power J; Gibbs P
    Asia Pac J Clin Oncol; 2017 Aug; 13(4):314-321. PubMed ID: 27885818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
    Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
    Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
    Nagaoka T; Osumi H; Ueno T; Ooki A; Wakatsuki T; Nakayama I; Ogura M; Takahari D; Chin K; Matsueda K; Yamaguchi K; Shinozaki E
    Int J Clin Oncol; 2023 Sep; 28(9):1191-1199. PubMed ID: 37349660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
    Iwamoto S; Takahashi T; Tamagawa H; Nakamura M; Munemoto Y; Kato T; Hata T; Denda T; Morita Y; Inukai M; Kunieda K; Nagata N; Kurachi K; Ina K; Ooshiro M; Shimoyama T; Baba H; Oba K; Sakamoto J; Mishima H
    Ann Oncol; 2015 Jul; 26(7):1427-33. PubMed ID: 25908603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment.
    Bai L; Zhang DS; Wu WJ; Ren C; Wang DS; Wang F; Qiu MZ; Xu RH
    Med Oncol; 2015 Feb; 32(2):469. PubMed ID: 25582893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
    van Dijk E; van Werkhoven E; Asher R; Mooi JK; Espinoza D; van Essen HF; van Tinteren H; van Grieken NCT; Punt CJA; Tebbutt NC; Ylstra B
    Int J Cancer; 2022 Oct; 151(7):1166-1174. PubMed ID: 35489024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
    Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
    Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
    Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.
    Huang W; Zhang H; Tian Y; Cha Y; Xiong H; Yuan X
    J Clin Pharm Ther; 2022 Apr; 47(4):531-538. PubMed ID: 35218209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
    Yamamoto S; Nagashima K; Kawakami T; Mitani S; Komoda M; Tsuji Y; Izawa N; Kawakami K; Yamamoto Y; Makiyama A; Yamazaki K; Masuishi T; Esaki T; Nakajima TE; Okuda H; Moriwaki T; Boku N
    BMC Cancer; 2021 Oct; 21(1):1159. PubMed ID: 34715820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
    Suzuki T; Shinozaki E; Osumi H; Nakayama I; Ota Y; Ichimura T; Ogura M; Wakatsuki T; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):307-313. PubMed ID: 31065729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.
    Zhou YW; Long YX; Chen Y; Liu JY; Pu D; Huang JY; Bi F; Li Q; Gou HF; Qiu M
    Cancer Med; 2021 May; 10(10):3388-3402. PubMed ID: 33939281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
    Tanioka H; Shimada K; Tsuji A; Kochi M; Kim HM; Takahashi T; Denda T; Takagane A; Watanabe T; Kotaka M; Nakamura M; Sunakawa YU; Takeuchi M; Ichikawa W; Fujii M
    Anticancer Res; 2022 May; 42(5):2675-2681. PubMed ID: 35489740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients.
    Ozcelik M; Odabas H; Ercelep O; Yuksel S; Mert AG; Aydin D; Surmeli H; Isik D; Isik S; Oyman A; Oven Ustaalioglu BB; Aliustaoglu M; Gumus M
    Clin Transl Oncol; 2016 Jun; 18(6):617-24. PubMed ID: 26459249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
    Slavicek L; Pavlik T; Tomasek J; Bortlicek Z; Buchler T; Melichar B; Vyzula R; Prausova J; Finek J; Majek O; Dusek L
    BMC Gastroenterol; 2014 Mar; 14():53. PubMed ID: 24666582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.